Amphion Innovations PLC DataTern Receives Favourable Appeal Ruling (3127B)
January 06 2015 - 2:00AM
UK Regulatory
TIDMAMP
RNS Number : 3127B
Amphion Innovations PLC
06 January 2015
Amphion Innovations plc
("Amphion" or "the Company")
(LSE: AMP)
Subsidiary Company DataTern Receives Favourable Appeal
Ruling
The Board of Amphion, a developer of medical, life science and
technology businesses, announces today that DataTern Inc.
("DataTern"), a wholly-owned subsidiary of the Company, has
received a favourable decision on its appeal to the United States
Court of Appeals for the Federal Circuit. The appeal arose out of
the United States District Court for the District of Massachusetts
grant of summary judgment that the defendant, MicroStrategy, Inc.,
and several other defendants, did not infringe U.S. Patent No.
6,101,502 (the "'502 Patent'").
In concluding that DataTern's claim construction was correct,
and that the District Court had erred in using a different more
narrow interpretation, the Federal Circuit vacated the summary
judgment and remanded the case back to the District Court so that
DataTern may proceed with its contentions that MicroStrategy, and
several other defendants, infringe the '502 Patent' under the
corrected claim construction. MicroStrategy sells business
intelligence and analytics software platforms used by other
defendants.
Richard Morgan, CEO of Amphion, said: "This result confirms our
view that the '502 Patent' has been infringed. The '502 Patent' is
directed to how object oriented software applications access data
stored in a relational database. Such applications are widely used
and most databases in use today are relational databases. We
continue to believe that companies that are using or want to use
our patented technology will wish to enter into equitable licensing
agreements. Our goal remains to generate a fair and reasonable
return on the very substantial investment we have made over many
years in the development of this innovative technology."
For further information please contact:
Amphion Innovations plc
Charlie Morgan
+1 212 210 6224
Yellow Jersey PR
Dominic Barretto / Fiona Walker
+44 7768 537 739
Panmure Gordon Limited
Freddy Crossley / Fred Walsh / Duncan Monteith (Corporate
Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 020 7886 2500
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and
technology businesses.
We use our extensive experience in company building to invest
and build shareholder value in high growth companies in the US and
UK. Amphion has significant shareholding in 7 Partner Companies
developing proven technologies targeting substantial commercial
marketplaces. The Amphion model has been refined to optimise the
commercialisation of patents and other intellectual property within
the Partner Companies. The Partner Companies collectively own or
control over 200 separately identified pieces of intellectual
property, a number which grows rapidly each year.
On the web: www.amphionplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUVRVRVVAARAR
Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Apr 2023 to Apr 2024